Purpose of the Study

Helios Clinical Research is conducting a clinical research study related to advanced cancers previously treated with PD-1/PD-L1 immune checkpoint inhibitors. The purpose of this study is to assess ORR, as determined by Investigator assessment per RECIST v1.1. The research team is seeking men and women who meet the eligibility criteria, including men and women ≥ 18 years of age, to learn whether they may qualify.

Study Requirements

  • Have signed and dated an IRB/IEC approved written informed consent form
  • Be willing and able to comply with the scheduled visits, treatment schedule, procedures, laboratory tests, and other requirements of the study
  • Have previously received treatment with PD-1/PD-L1 immune checkpoint inhibitors 

Potential Benefits of Participation

Maginfying

Access to new treatments that are not yet available to the general public.

Hand Heart

Personalized medical attention from leading healthcare professionals.

Helios

Compensation provided to qualified participants

Study Locations

These studies are currently enrolling at the following sites:

The Oncology Institute Powered by Helios - Ft. Lauderdale, FL

About Helios Clinical

Helios Clinical is dedicated to advancing medical research through innovative clinical trials.
Our mission is to discover new ways to improve patient health and outcomes.
We collaborate with leading healthcare professionals and scientists
to ensure the highest standards of research and care for our participants.